Cardiac Arrhythmias in Dravet Syndrome

NCT ID: NCT02415686

Last Updated: 2018-09-07

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 59 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2015-06-30
• Study Completion Date: 2018-08-29

Brief Summary

SUMMARY

Rationale:

People with Dravet Syndrome (DS), a rare epilepsy syndrome, have a high risk of Sudden Unexpected Death in Epilepsy (SUDEP). Mouse models indicated that the responsible sodium channel mutation (SCN1A) not only alters cortical excitability but also increases the propensity to arrhythmias. Little is known yet about the prevalence of seizure-induced arrhythmias in human DS subjects.

Objective:

To assess the prevalence of cardiac arrhythmias in DS and to compare the prevalence of cardiac arrhythmias between DS subjects and subjects with other types of epilepsy.

Study design:

Observational study.

Study population:

Subjects with Dravet syndrome and a known pathogenic SCN1A mutation, seizure frequency ≥ 1/week (all seizure types except for absences or myoclonias), age ≥ 6 years and no signs of self-harm. Each case will be matched to two historical controls (age +/- 5 years) from the EEG databases of the participating centres. Only those controls with two or more recorded seizures will be matched to the cases.

Intervention:

Not applicable

Main study parameters/endpoints:

Ictal asystole Ictal bradycardia Ictal QT-shortening/lengthening

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

Participation does not carry risks. The sensor is wearable and miniaturised, thus minimising discomfort. If this nevertheless may occur, the study can be terminated. This study provides specific tools to investigate the seizure-related heart rate response. Subjects may thus benefit from participation by identification of otherwise unknown arrhythmias. The rationale of the study (the high SUDEP risk and the evidence in animal studies for arrhythmic cause of sudden death) specifically applies to DS, a rare epileptic syndrome including minors and incapacitated persons. The investigators believe that the lack of risks, the potential diagnostic benefit, the minimal intervention with novel and wearable sensors and the possibility to terminate the study in case of discomfort, justifies the study in this patient group.

Conditions

Epilepsy

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

Criteria:

Cases must meet all of the following criteria:

1. DS with a known pathogenic SCN1A mutation

2. seizure frequency ≥ 1/week (all seizure types expect for absences or myoclonias)

3. no self-harm

4. age ≥ 6 years

Each case will be matched to two historical controls (age +/- 5 years). Controls will meet the following criteria:

1. definite diagnosis of epilepsy

2. no clinical suspicion of DS

3. at least two seizures recorded (all seizure types expect for absences or myoclonias) during video-EEG registration.

4. age ≥ 6 years

• Minimum Eligible Age: 6 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Epilepsiefonds

UNKNOWN

Sponsor Role: collaborator

Stichting Epilepsie Instellingen Nederland

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Roland Thijs, Dr.

Role: PRINCIPAL_INVESTIGATOR

Stichting Epilepsie Instellingen Nederland (S.E.I.N.)

Locations

Universität Bonn

Bonn, North Rhine-Westphalia, Germany

Stichting Epilepsie Instellingen Nederland (SEIN)

Heemstede, Achterweg 5, Netherlands

Great Ormond Street Hospital

London, South East, United Kingdom

Countries

Germany; Netherlands; United Kingdom

Other Identifiers

NL48765.058.15

Identifier Type: -

Identifier Source: org_study_id